Get the Stockscreener App
13.22
1.07%
0.14
After Hours:
13.12
-0.10
-0.76%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Viatris Inc stock is traded at $13.22, with a volume of 4.67M.
It is up +1.07% in the last 24 hours and up +15.56% over the past month.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
See More
Previous Close:
$13.08
Open:
$13.08
24h Volume:
4.67M
Relative Volume:
0.63
Market Cap:
$15.73B
Revenue:
$15.05B
Net Income/Loss:
$-883.30M
P/E Ratio:
8.6405
EPS:
1.53
Net Cash Flow:
$1.89B
1W Performance:
+0.69%
1M Performance:
+15.56%
6M Performance:
+26.99%
1Y Performance:
+41.54%
1-Day Range:
$13.01
$13.23
1-Week Range:
$12.94
$13.55
52-Week Range:
$9.08
$13.62
Viatris Inc Stock (VTRS) Company Profile
Name
Viatris Inc
Sector
Phone
(724) 514-1465
Address
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
13.22 | 15.73B | 15.05B | -883.30M | 1.89B | 1.53 |
|
ZTS
Zoetis Inc
|
176.74 | 80.59B | 9.15B | 2.43B | 2.31B | 4.92 |
|
HLN
Haleon Plc Adr
|
9.72 | 44.17B | 14.26B | 1.55B | 0 | 0.3327 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.57 | 42.61B | 30.27B | 1.93B | 3.45B | 0.444 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.57 | 18.77B | 16.77B | -959.00M | 1.37B | -2.00 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-19-24 | Resumed | Jefferies | Buy |
| Oct-23-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-23-23 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-24-23 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-17-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-27-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-10-22 | Upgrade | UBS | Sell → Neutral |
| Nov-08-22 | Upgrade | Piper Sandler | Underweight → Neutral |
| Oct-21-22 | Resumed | Jefferies | Hold |
| Jun-14-22 | Initiated | UBS | Sell |
| May-10-22 | Downgrade | Piper Sandler | Neutral → Underweight |
| Mar-01-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-01-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-15-21 | Initiated | Citigroup | Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Mar-08-21 | Downgrade | Goldman | Buy → Neutral |
| Mar-02-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-26-21 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-05-21 | Initiated | Argus | Hold |
| Dec-14-20 | Initiated | Bernstein | Mkt Perform |
View All
Viatris Inc Stock (VTRS) Latest News
2 Generic Drug Stocks Ready to Surge in 2025 - MarketBeat
Hypopituitarism Treatment Market to Witness Huge Growth - openPR
Hypovolemic Shock Market Growth Analysis: Industry Expansion - openPR
UK CMA fines Viatris for breaching order during Theramex deal probe - World Pharmaceutical Frontiers
Viatris fined in Morocco over merger notification, sources say - MSN
Vitaris fined in Morocco over merger notification, sources say - MSN
Morocco fines Viatris 7.58 million dirhams over Mylan-Pfizer merger - MSN
Viatris Reports Third Quarter Financial Results for 2024 - GuruFocus.com
UK watchdog fines Viatris $1.9 mln over rule breach in Theramex probe - Reuters.com
Viatris Fined £1.5M For Failing To Comply With CMA Order - Law360
Viatris fined £1.5M for failure to comply with CMA order - MSN
Viatris fined £1.5M for failure to comply with CMA order (NASDAQ:VTRS) - Seeking Alpha
UK watchdog fines Viatris $1.9 million over rule breach in Theramex probe - Marketscreener.com
Viatris Fined £1.5M for CMA Order Breach - Mirage News
Viatris fined £1.5m for failure to comply with CMA order - GOV.UK
Ampicillin Market to Continue Impressive Measured Growth - openPR
Viatris fined in Morocco over merger notification, sources say By Reuters - Investing.com
Viatris Fined in Morocco Over Merger Notification, Sources Say - U.S News & World Report Money
Psoriasis Biosimilars Market Key Players AnalysisMerck KGaA, - openPR
United States Active Pharmaceutical Ingredients (API) Market May See a Big Move | Merck, Novartis, Viatris, Lupin - openPR
Ex-Dividend Reminder: NextEra Energy, CRH and Viatris - Nasdaq
Viatris Inc.: Expansion of Innovative Portfolio As A Vital Factor Driving Growth!Major Drivers - Smartkarma
Viatris Inc. Rings the Closing Bell - Nasdaq
Catecholamines Drugs Market Specialized New Report, See Growth - openPR
Cerebral Palsy Treatment Market Growth Overview: - openPR
Transdermal Skin Patches Market Overall Study Report 2024-2031 - openPR
Safecor Health Acquires Viatris’ U.S. Unit-Dose Packaging Business - citybiz
Safecor Health Announces Acquisition of Viatris' U.S. Unit-Dose Packaging Business - PR Newswire
VSCP-backed Safecor Health picks up Viatris Inc’s US unit-dose packaging business - PE Hub
Influenza Vaccines Industry May See a Big Move | BIKEN, Viatris, Sinovac Biotech - openPR
Chris Davis's Strategic Acquisition of Viatris Inc Shares - GuruFocus.com
Viatris's SWOT analysis: generic drug maker's stock faces growth hurdles - Investing.com
Viatris Inc's chief accounting officer sells $346,686 in stock - Investing.com India
Viatris Inc's chief accounting officer sells $346,686 in stock By Investing.com - Investing.com Australia
YieldBoost VTRS To 8.9% Using Options - Nasdaq
Is Viatris Inc (VTRS) Set to Underperform? Analyzing the Factors Limiting Growth - GuruFocus.com
Viatris Outshines Wall Street With Unexpected Profit Gains - Finimize
Viatris Inc Stock (VTRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.03%
0.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):